quinta-feira, 1 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· July 6, 2026

Bank of America resets Nike stock target on recovery plan

View original at finance.yahoo.com

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Nike's fourth quarter 2026 results were in line with expectations, but the bigger change was the company's weaker sales outlook

    60% confidence

  • Hutchinson lowered the price target because Nike's sales recovery is taking longer than expected

    60% confidence

  • Earnings expectations remain largely intact because gross-margin expansion is expected to begin in the first quarter, earlier than previously expected, and because Nike is using cost controls to protect profit

    60% confidence

  • BofA kept its fiscal 2027 earnings estimate at $1.60 a share, saying lower sales should be offset by cost control and stronger gross margin

    60% confidence

  • Nike's latest earnings summed up as a 'Choppy recovery'

    60% confidence

  • BofA raised its fiscal 2028 earnings estimate to $2.13 from $2.00, reflecting lower selling, general, and administrative expenses

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,317 documentos-fonte arquivados
Consulte estes dados → isubstrate.com